Skip to main content

Table 3 PsA resistance risk factors for clinical outcomes

From: Real-world use of ceftolozane/tazobactam: a systematic literature review

Citation, study design, location N C/T Patient/infection description Analysis Variable Proportion of patients with either outcome with variable p-value
Rodriguez-Nunez et al. 2019 [28]
Retrospective, multicenter
International
90 Drug-resistant PsA RTIs (76.7% XDR; 23.3% MDR) Univariate regression XDR PsA infection Survivors
(N = 65)
Non-survivors
(N = 25)
.308
73.8%
(48/65)
84.0%
(21/25)
Diaz-Cañestro et al. 2018 [30]
Prospective,
single center
Spain
58 PsA (86.2% XDR; 10.3% MDR) infections, including RTIs (60.3%), UTIs (17.2%), and IAIs (6.9%) Univariate regression   Clinical
cure
(N = 35)
Clinical failure (N = 21)  
Resistance profile    .045
XDR PsA infection 82.8%
(29/35)
100.0%
(21/21)
MDR PsA infection 17.1%
(6/35)
0.0%
(0/21)
  1. p-value < 0.05 indicates a significant difference are shown in bold
  2. C/T: Ceftolozane/tazobactam; IAI: Intra-abdominal infection; MDR: Multidrug-resistant; PsA: Pseudomonas aeruginosa; RTI: Respiratory tract infection; UTI: Urinary tract infection; XDR: Extensively-drug-resistant